Effects of Intensive cART During Acute/Early HIV Infection: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Effects of Intensive cART During Acute/Early HIV Infection (NCT01154673), a randomized phase 2, phase 3 study. The primary outcome is Change in Proviral HIV-1 DNA in Total CD4+ T-cells From Baseline to Week 48 in Participants Randomized to the Intensified Arm Versus the Control Arm Who Received Placebo in Addition to Standard HAART..

2. Clinical Question

3. Trial Design

The registry identifies this as a randomized, parallel-group trial with quadruple masking, listed in Phase 2 and Phase 3. The sponsor was the University of Toronto, and the status is completed. The recorded start is 2011-11, with primary completion in 2014-09. The registry enrollment is 32. The record does not explain who was included in the quadruple masking designation or how masking was maintained.

Participants were assigned to Intensive HAART or a Placebo Arm. Intensive HAART consisted of raltegravir, maraviroc, emtricitabine/tenofovir, and lopinavir/ritonavir. The registry specifies raltegravir 400 mg BID, maraviroc 150mg BID, emtricitabine 200mg /tenofovir 300mg QD, and lopinavir 400 mg/ritonavir 100mg BID for 96 weeks. In the Placebo Arm, placebo replaced raltegravir and maraviroc while the standard HAART backbone was continued. The placebo period was 48 weeks, after which participants were offered open-label raltegravir and maraviroc.

The primary outcome is described as change in proviral HIV-1 DNA in total CD4+ T-cells from baseline to Week 48. The registry reports median arm values and full ranges, as well as a linear regression analysis of mean difference in final values. The distinction between the change named in the endpoint and the final-value wording in the analysis is not clarified in the registry record. The trial's detailed allocation procedure, eligibility criteria beyond acute HIV infection, and operational analysis plan are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Change in Proviral HIV-1 DNA in Total CD4+ T-cells From Baseline to Week 48 in Participants Randomized to the Intensified Arm Versus the Control Arm Who Received Placebo in Addition to Standard HAART., measured over Baseline to Week 48.

The primary endpoint concerns proviral HIV-1 DNA in total CD4+ T-cells, measured as HIV DNA copies per million CD4 cells. The endpoint title defines the comparison as change from baseline to Week 48. The description says peripheral-blood CD4 T-cells were assessed at 48 weeks relative to baseline using a quantitative HIV PCR assay. It frames the comparison as standard HAART versus the intensified regimen.

Proviral HIV DNA is relevant to this study because the trial focuses on HIV reservoir decay during acute or early infection. In general, a biomarker endpoint can provide a biological measure related to a treatment hypothesis, while not necessarily representing a direct clinical outcome experienced by a participant. The registry does not report a clinical outcome as the primary endpoint.

The outcome parameter is listed as a median with full range. The Intensive HAART arm summary reports 279.0, with a range from 26.0 to 2836.0; the Placebo Arm summary reports 244.0, with a range from 2.5 to 5186.0. The registry does not clearly state whether these arm-level values represent endpoint levels or changes, despite the endpoint title specifying change. That ambiguity matters when interpreting the summaries and should not be resolved by assumption.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry reports two kinds of summaries for the primary endpoint: arm-level medians with full ranges, and a regression analysis reporting a mean difference in final values. These summarize data in different ways. A median identifies the central ranked observation, while a mean uses all values and can be influenced by extreme observations. The full range records the lowest and highest values; it does not show how values are distributed between those extremes.

What does the confidence interval describe?

In general, a confidence interval expresses the uncertainty around an estimated quantity under the assumptions of the statistical method. The reported estimate is 0.2, and its 95% confidence interval runs from -.006 to 0.4. Because the interval includes zero, it does not rule out no difference under that model. Its span also indicates that the data are compatible with a range of possible contrasts. A confidence interval is not a guarantee that the true value lies within its particular endpoints, and it does not incorporate uncertainty from unreported design or analysis choices.

How should the p-value be read?

The reported p-value is 0.056. In general, a p-value describes how unusual data at least as incompatible with a null hypothesis would be if that hypothesis and the model assumptions held. It is not the probability that the null hypothesis is true, nor a measure of clinical importance. The registry does not state the decision rule for this endpoint. The planning assumptions mention a two-sided significance level of 0.05, but that is described for planning illustrations and should not automatically be treated as the declared primary analysis threshold.

Why do the median summaries and regression estimate differ?

The arm summaries list median values, whereas the analysis parameter is a mean difference in final values. Medians and means respond differently to skewness and extreme observations. The reported full ranges are wide, which makes it especially important not to assume that the median contrast must match a mean-based estimate. The registry does not report the participant-level distribution, regression specification, adjustment variables, or any transformation. It is therefore not possible to determine from the record why the two types of summary have their particular values.

What is the role of randomization and masking?

Random assignment is intended, in general, to reduce systematic differences between treatment groups at allocation. Masking can reduce the influence of expectations on treatment delivery or assessment, depending on who is masked and how outcomes are assessed. This record lists randomized allocation and quadruple masking, but does not describe the allocation procedure, concealment, the masked parties, or the success of masking. The labels alone do not establish how those procedures were implemented.

Why can over-dispersion matter?

In general, over-dispersion means that observed variability is greater than a statistical model expects. If a model does not account for that extra variability, its standard errors and uncertainty estimates may be too small. The wide full ranges make variation worth considering, but the registry does not report a dispersion assessment, diagnostic checks, or a model addressing over-dispersion. No conclusion about whether over-dispersion affected this analysis can be drawn from the record.

What can planning illustrations say?

Planning calculations are conditional illustrations, not observed results and not observed power. The described assumptions use a two-sided significance level of 0.05, equal allocation, and a normal approximation, with the effect to detect expressed as a fraction of the observed effect. Such calculations depend on those assumptions and on the estimated effect used as a planning reference. The registry record does not report the trial's own sample-size justification or target power. No planning count should be mistaken for the number enrolled or analyzed, or as evidence that the trial had a particular probability of detecting an effect.

Overall, the analysis is interpretable as a reported regression contrast with a confidence interval and p-value, but important details remain unspecified. The registry record does not report the model covariates, handling of missing measurements, assumptions about outcome distribution, a prespecified analysis population, or whether analyses were adjusted for baseline values. These omissions limit independent evaluation and reproduction of the reported analysis.

10. Analyses Reported by the Sponsor

The registry reports the sponsor's comparative analysis as linear regression of mean difference in final values: 0.2, with a 95% confidence interval from -.006 to 0.4 and p = 0.056. The arm-level outcome values are reported as medians with full ranges. These summaries do not constitute a recalculation of the sponsor's regression result, and the registry record does not include participant-level data or enough regression detail to reproduce it.

No recalculated estimate is reported in the registry record. The sponsor's own analysis therefore remains the relevant reported comparative estimate. The median summaries should not be substituted for that regression result: a median contrast and a regression-based mean difference are distinct quantities. The endpoint title refers to change from baseline, while the analysis parameter is described as mean difference in final values; the registry does not explain that difference in wording. Any interpretation should preserve this limitation rather than imply that the analysis has been independently confirmed.

The confidence interval includes zero, and the reported p-value is 0.056. These statistics describe uncertainty under the sponsor's stated analysis, not proof of equivalence or a measure of clinical importance. The registry does not report sufficient information to assess model assumptions or the effect of missing observations.

11. Multiplicity, Missing Data and Analysis Populations

The registry lists one outcome measure and one analysis. It does not report a multiplicity adjustment or a broader statistical analysis plan that would identify all outcomes, contrasts, or interim looks considered. With only the registry record, it is not possible to determine whether the reported primary analysis was the sole planned comparison or how any additional analyses were handled. The absence of a reported adjustment does not establish that multiplicity was either present or absent in the conduct of the study.

The primary endpoint is described as change from baseline to Week 48, but the reported regression parameter is mean difference in final values. The registry does not clarify whether baseline values were included as covariates, whether change scores were analyzed, or whether another approach was used. It also does not report a prespecified analysis population, a missing-data method, the number of missing Week 48 outcomes, or reasons for missingness. The primary outcome summaries list 14 participants in Intensive HAART and 16 in the Placebo Arm, while the registry enrollment is 32. Those figures alone do not explain whether records were unavailable, excluded, or analyzed under a particular population definition.

In general, missing outcome data can affect both precision and the interpretation of group comparisons, especially when missingness relates to treatment or outcome. A complete-case analysis, imputation, or model-based approach would rely on different assumptions. The record does not state which, if any, was used, so no assumption about missingness can be evaluated.

The registry also does not report an interim analysis plan, stopping rules, sample-size justification, or the handling of protocol deviations. The sample-size planning assumptions described for planning illustrations are not a substitute for a trial-specific analysis plan. These omissions make it difficult to assess whether the reported comparison follows a prespecified framework or how robust it is to alternative analysis decisions.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Serious events with the highest arm-level rate: neutropenia (6.2%).

The adverse-event summaries list one serious adverse event in the Intensive HAART group and zero in the Placebo Arm. The recorded number at risk for serious events is 16 in each group. The registry lists neutropenia at 6.2% among the top serious terms. The adverse-event summary does not make clear how that term's percentage was derived, so it should be read as reported rather than converted into a count or assigned to a group by inference.

The summary records zero other adverse events in both groups, with 16 at risk in each. Death counts are not reported in the registry record. These figures are descriptive and do not establish a comparative safety profile: the record does not provide event definitions, severity grading beyond serious status, exposure-adjusted rates, detailed follow-up, or a statistical comparison. Sparse event counts also provide limited precision for estimating differences. A count of zero in a group does not prove that an event cannot occur, and a single event does not by itself establish a treatment-related effect. The registry record does not provide an attribution assessment for the serious event.

13. What the Result Does, and Does Not, Mean

The posted results show that the trial compared an intensified antiretroviral regimen with placebo added to standard HAART in people with acute HIV infection, focusing on proviral HIV-1 DNA in total CD4+ T-cells. The primary outcome summaries report medians of 279.0 for Intensive HAART and 244.0 for the Placebo Arm, with full ranges of 26.0 to 2836.0 and 2.5 to 5186.0. The regression analysis reports a mean difference in final values of 0.2, a 95% confidence interval from -.006 to 0.4, and p = 0.056.

These results describe the registry's reported summaries and analysis. The confidence interval includes zero and permits uncertainty about the magnitude and direction of the contrast under the reported model. The p-value does not establish the probability that the treatment has no effect or that the observed contrast is important. The registry does not clarify whether the arm values represent change or endpoint level, despite the endpoint title's focus on change from baseline. Nor does it provide the analysis details needed to resolve this ambiguity.

The record does not establish whether intensified treatment changes HIV reservoir biology, whether any biomarker contrast translates into a clinical outcome, or whether the treatment is beneficial or harmful. It reports no primary clinical outcome, and no conclusions about individual care follow from these statistics. The serious adverse-event summaries are also too limited to support broad comparative safety conclusions.

In general, a randomized comparison can help estimate differences between assigned groups, but interpretation depends on the conduct of the trial, completeness of follow-up, endpoint definition, and analysis methods. Several of those details are not reported in the registry record. The appropriate conclusion is therefore bounded: a regression estimate and uncertainty interval are recorded, alongside arm-level medians and ranges, but the precision and methodological detail do not support a stronger claim about the underlying effect.

14. Why This Trial Matters Statistically

This trial raises a statistical question that is common in early-stage treatment research: how to interpret a biological endpoint when the study is comparatively small and the measured outcome varies widely. Proviral HIV-1 DNA in CD4+ T-cells is used as a measure related to reservoir decay, while the posted comparison focuses on a treatment regimen that adds raltegravir and maraviroc to standard HAART. The trial therefore connects a biological hypothesis to an endpoint that is not itself a direct clinical outcome.

The results also illustrate why the reported summary and analysis method matter. Arm medians and full ranges describe the observed groups differently from a regression estimate of mean difference. The registry's confidence interval is wide enough to include zero, and the analysis estimate is not accompanied by details about covariate adjustment, transformation, or missing-data handling. A single estimate should not be read without its uncertainty or its methodological context.

Randomized allocation and masking are important design features, but their labels do not replace reporting on implementation and analysis. The registry record lists both, yet leaves several operational details unspecified. Clear reporting of the endpoint's exact scale, the analysis population, baseline handling, and missing observations would make it easier to assess precision and reproducibility.

The study also emphasizes the distinction between planning and evidence. Planning illustrations based on an observed effect are conditional calculations, not observed power and not proof that the original design was adequate. The trial-specific sample-size justification is not reported in the registry record. Statistically, the result is most informative when treated as an uncertain estimate that can motivate careful interpretation, rather than as a categorical answer about the treatment or the clinical significance of a biomarker difference.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific limitations arise from the information recorded. The primary endpoint title specifies change from baseline to Week 48, while the reported analysis is described as a mean difference in final values. The arm-level summaries are medians, and the registry does not explicitly identify whether those values are changes or final levels. This leaves uncertainty about the precise quantity represented by each result.

The primary outcome summaries include 14 participants in Intensive HAART and 16 in the Placebo Arm, while enrollment is recorded as 32. The registry does not explain the relationship between these numbers or report missing outcome counts and reasons. It does not specify the analysis population, how missing data were handled, or whether the analysis was adjusted for baseline values. The degree to which these choices could affect the estimate cannot be assessed from the record.

The comparative analysis is described as linear regression, but model covariates, transformations, diagnostics, and the contrast's direction are not reported. That limits independent reproduction and interpretation of the estimate's scale. The arm summaries provide medians and full ranges but not further distributional detail, and the full ranges are broad. The record does not report sensitivity analyses or a method for addressing possible departures from model assumptions.

Finally, the trial-specific sample-size justification, analysis plan, multiplicity strategy, and interim analysis details are not reported in the registry record. The intervention schedules also differ after 48 weeks because the placebo group was offered open-label raltegravir and maraviroc, while the primary endpoint is at Week 48. The record does not provide later comparative outcome results in the posted primary outcome summary. These limitations constrain conclusions to the outcome and analysis as recorded.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Effects of Intensive cART During Acute/Early HIV Infection — NCT01154673.
• Registry record last updated 2016-04-05; status last verified 2016-03.
• Results first posted 2016-04-05.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT01154673 is a completed randomized, parallel-group trial with quadruple masking, sponsored by the University of Toronto. The registry lists Phase 2 and Phase 3, enrollment of 32, and a condition of acute HIV infection. The trial compared intensified HAART including raltegravir and maraviroc with placebo added to standard HAART.

The primary endpoint concerns proviral HIV-1 DNA in total CD4+ T-cells from baseline to Week 48. The posted arm summaries give medians and full ranges, and the registry reports a linear regression estimate of mean difference in final values: 0.2, with a 95% confidence interval from -.006 to 0.4 and p = 0.056. The endpoint wording and analysis description are not fully reconciled in the record. Serious adverse-event summaries list one event in Intensive HAART and zero in the Placebo Arm. Important details about missing data, analysis populations, model specification, and the trial's sample-size justification are not reported in the registry record.